Brisbane and Melbourne, Australia, 22 December 2008: Biotechnology companies Progen Pharmaceuticals Limited (ASX:PGL; NASDAQ:PGLA) and Avexa Limited (ASX: AVX) today announced the signing of an ...

Progen shareholders will now hold 56% of the merged group, while Avexa shareholders will maintain 44%. The new entity will be known as Avexa Pharmaceuticals and will have Avexa management control.

Starting out in 1983 as a pioneer in antibody manufacturing, PROGEN has since become a globally operating biotech company that serves the life sciences and pharma sector. Building on our core ...

Brisbane-based Progen Industries Ltd announced the sale of its Life Sciences business, allowing the biotech to focus on its core business of developing a cure for cancer. The Life Sciences ...

Its chief scientific officer, Dr. Laurence Marton, the former chair of the Department of Laboratory Medicine at the University of California, San Francisco, will take a job at Progen. The upfront ...

Could Progen stock see similar gains? Why not! A small biotech firm with exciting research, small market cap, and positive news could easily see more positive price movement. If you’re one of ...